Aurinia Pharmaceuticals Inc. (AUPH): restructuring charge — Aurinia reports 2023 net product revenue up 53% to $158.5M; ends strategic review, initiates $150M buyback

Aurinia Pharmaceuticals Inc.

Net product revenue $158.5M (+53% YoY); net loss $78.0M ($0.54/shr) vs $108.2M loss in 2022.
Discontinues AUR200/AUR300 development; expects $11-15M Q1'24 charge and $50-55M annual savings; headcount cut ≥25% (non-commercial).
Board authorizes up to $150M share repurchase; max subject to Canadian regulatory approval; purchases start Feb 21, 2024.
Strategic review concluded after engaging 60+ parties; one non-binding expression of interest did not lead to formal offer.
Reaffirms 2024 net product revenue guidance of $200-220M; 2,066 patients on LUPKYNIS at year-end (vs 1,525).

item 2.02 item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. updated its quarter and year ended December 31, 2023 guidance (reaffirmed).

Period: quarter and year ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 15, 2024, Aurinia Pharmaceuticals Inc. (Aurinia) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Aurinia Pharmaceuticals Inc. announced a restructuring with charges of approximately $11 - $15 million affecting AUR200 and AUR300 research and development programs.

Type: restructuring
Charge: approximately $11 - $15 million
Affected area: AUR200 and AUR300 research and development programs

Exact text from the filing

This will result in a one-time charge in the first quarter of 2024 of approximately $11 - $15 million and expected operational cost savings of approximately $50 - $55 million annually, with approximately 75% being recognized in 2024 excluding the one-time restructuring charge in the first quarter of 2024.

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.